keyword
MENU ▼
Read by QxMD icon Read
search

Breast cancer and fertility

keyword
https://www.readbyqxmd.com/read/28093732/long-term-hormone-therapy-for-perimenopausal-and-postmenopausal-women
#1
REVIEW
Jane Marjoribanks, Cindy Farquhar, Helen Roberts, Anne Lethaby, Jasmine Lee
BACKGROUND: Hormone therapy (HT) is widely provided for control of menopausal symptoms and has been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women. This is an updated version of a Cochrane review first published in 2005. OBJECTIVES: To assess effects of long-term HT (at least 1 year's duration) on mortality, cardiovascular outcomes, cancer, gallbladder disease, fracture and cognition in perimenopausal and postmenopausal women during and after cessation of treatment...
January 17, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28087390/family-building-after-breast-cancer-considering-the-effect-on-adherence-to-adjuvant-endocrine-therapy
#2
Catherine Benedict, Bridgette Thom, Eleonora Teplinsky, Jane Carleton, Joanne F Kelvin
Adherence to endocrine therapy (ET) is a longstanding problem in breast cancer (BC) survivorship care, particularly among younger women. Younger patients have reported lower ET initiation rates and greater rates of early discontinuation and are considered an "at risk" group for nonadherence. For women who hope to have children in the future, concerns about premature menopause and the implications of postponing childbearing for the 5 to 10 years of ET are widespread. Preliminary evidence suggests that prioritizing fertility, along with concerns about side effects, leads to ET noninitiation and early discontinuation...
December 24, 2016: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28056411/chemotherapy-related-late-adverse-effects-on-ovarian-function-in-female-survivors-of-childhood-and-young-adult-cancer-a-systematic-review
#3
REVIEW
Annelies Overbeek, Marleen H van den Berg, Flora E van Leeuwen, Gertjan J L Kaspers, Cornelis B Lambalk, Eline van Dulmen-den Broeder
BACKGROUND: Anti-cancer treatment may reduce the fertile life span and induce premature menopause. This review aims to provide an overview of the available literature on effects of chemotherapy only on the incidence of ovarian dysfunction and to evaluate the relationship between dose of chemotherapy, age at time of treatment, and time since treatment in female survivors of childhood and young adult cancer. METHODS: A comprehensive search of electronic databases was performed (search date December 2015)...
November 24, 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28035489/the-association-between-a-history-of-gestational-diabetes-mellitus-and-future-risk-for-female-malignancies
#4
Oded Fuchs, Eyal Sheiner, Mihai Meirovitz, Ehud Davidson, Ruslan Sergienko, Roy Kessous
OBJECTIVE: To investigate whether patients with a history of gestational diabetes mellitus (GDM) have an increased future risk for female malignancies. STUDY DESIGN: A population-based study compared the incidence of long-term female malignancies (ovary, uterine, breast, and uterine cervix) in a cohort of women with and without a diagnosis of GDM. Deliveries occurred between the years 1988-2013, with a mean follow-up duration of 12 years. Women with known malignancies prior to the index pregnancy were excluded...
December 29, 2016: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/28024682/coming-of-age-women-s-sexual-and-reproductive-health-after-twenty-one-years-of-democracy-in-south-africa
#5
Diane Cooper, Jane Harries, Jennifer Moodley, Deborah Constant, Rebecca Hodes, Cathy Mathews, Chelsea Morroni, Margaret Hoffman
This paper is a sequel to a 2004 article that reviewed South Africa's introduction of new sexual and reproductive health (SRH) and rights laws, policies and programmes, a decade into democracy. Similarly to the previous article, this paper focuses on key areas of women's SRH: contraception and fertility, abortion, maternal health, HIV, cervical and breast cancer and sexual violence. In the last decade, South Africa has retained and expanded its sexual and reproductive health and rights (SRHR) policies in the areas of abortion, contraception, youth and HIV treatment (with the largest antiretroviral treatment programme in the world)...
November 2016: Reproductive Health Matters
https://www.readbyqxmd.com/read/27966219/oncofertility-program-implementation-increases-access-to-fertility-preservation-options-and-assisted-reproductive-procedures-for-breast-cancer-patients
#6
Joceline V Vu, Natalia C Llarena, Samantha L Estevez, Molly B Moravek, Jacqueline S Jeruss
BACKGROUND AND OBJECTIVES: Breast cancer treatment can cause premature ovarian failure, yet the majority of young cancer patients do not receive adequate education about treatment effects before initiating chemotherapy. We studied the impact of an oncofertility program on access to fertility preservation. METHODS: An oncofertility program was initiated to foster collaboration between oncologists and reproductive endocrinologists, and to help increase access to fertility preservation...
December 14, 2016: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27940355/temporary-ovarian-suppression-during-chemotherapy-to-preserve-ovarian-function-and-fertility-in-breast-cancer-patients-a-grade-approach-for-evidence-evaluation-and-recommendations-by-the-italian-association-of-medical-oncology
#7
REVIEW
Matteo Lambertini, Michela Cinquini, Ivan Moschetti, Fedro A Peccatori, Paola Anserini, Mario Valenzano Menada, Maurizio Tomirotti, Lucia Del Mastro
The development of premature ovarian failure and subsequent infertility are possible consequences of chemotherapy use in pre-menopausal women with early-stage breast cancer. Among the available strategies for fertility preservation, pharmacological protection of the ovaries using luteinising hormone-releasing hormone analogues (LHRHa) during chemotherapy has the potential to restore ovarian function and fertility after anticancer treatments; however, the possible efficacy and clinical application of this strategy has been highly debated in the last years...
January 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/27918777/global-regional-and-national-cancer-incidence-mortality-years-of-life-lost-years-lived-with-disability-and-disability-adjusted-life-years-for-32-cancer-groups-1990-to-2015-a-systematic-analysis-for-the-global-burden-of-disease-study
#8
Christina Fitzmaurice, Christine Allen, Ryan M Barber, Lars Barregard, Zulfiqar A Bhutta, Hermann Brenner, Daniel J Dicker, Odgerel Chimed-Orchir, Rakhi Dandona, Lalit Dandona, Tom Fleming, Mohammad H Forouzanfar, Jamie Hancock, Roderick J Hay, Rachel Hunter-Merrill, Chantal Huynh, H Dean Hosgood, Catherine O Johnson, Jost B Jonas, Jagdish Khubchandani, G Anil Kumar, Michael Kutz, Qing Lan, Heidi J Larson, Xiaofeng Liang, Stephen S Lim, Alan D Lopez, Michael F MacIntyre, Laurie Marczak, Neal Marquez, Ali H Mokdad, Christine Pinho, Farshad Pourmalek, Joshua A Salomon, Juan Ramon Sanabria, Logan Sandar, Benn Sartorius, Stephen M Schwartz, Katya A Shackelford, Kenji Shibuya, Jeff Stanaway, Caitlyn Steiner, Jiandong Sun, Ken Takahashi, Stein Emil Vollset, Theo Vos, Joseph A Wagner, Haidong Wang, Ronny Westerman, Hajo Zeeb, Leo Zoeckler, Foad Abd-Allah, Muktar Beshir Ahmed, Samer Alabed, Noore K Alam, Saleh Fahed Aldhahri, Girma Alem, Mulubirhan Assefa Alemayohu, Raghib Ali, Rajaa Al-Raddadi, Azmeraw Amare, Yaw Amoako, Al Artaman, Hamid Asayesh, Niguse Atnafu, Ashish Awasthi, Huda Ba Saleem, Aleksandra Barac, Neeraj Bedi, Isabela Bensenor, Adugnaw Berhane, Eduardo Bernabé, Balem Betsu, Agnes Binagwaho, Dube Boneya, Ismael Campos-Nonato, Carlos Castañeda-Orjuela, Ferrán Catalá-López, Peggy Chiang, Chioma Chibueze, Abdulaal Chitheer, Jee-Young Choi, Benjamin Cowie, Solomon Damtew, José das Neves, Suhojit Dey, Samath Dharmaratne, Preet Dhillon, Eric Ding, Tim Driscoll, Donatus Ekwueme, Aman Yesuf Endries, Maryam Farvid, Farshad Farzadfar, Joao Fernandes, Florian Fischer, Tsegaye Tewelde G/Hiwot, Alemseged Gebru, Sameer Gopalani, Alemayehu Hailu, Masako Horino, Nobuyuki Horita, Abdullatif Husseini, Inge Huybrechts, Manami Inoue, Farhad Islami, Mihajlo Jakovljevic, Spencer James, Mehdi Javanbakht, Sun Ha Jee, Amir Kasaeian, Muktar Sano Kedir, Yousef S Khader, Young-Ho Khang, Daniel Kim, James Leigh, Shai Linn, Raimundas Lunevicius, Hassan Magdy Abd El Razek, Reza Malekzadeh, Deborah Carvalho Malta, Wagner Marcenes, Desalegn Markos, Yohannes A Melaku, Kidanu G Meles, Walter Mendoza, Desalegn Tadese Mengiste, Tuomo J Meretoja, Ted R Miller, Karzan Abdulmuhsin Mohammad, Alireza Mohammadi, Shafiu Mohammed, Maziar Moradi-Lakeh, Gabriele Nagel, Devina Nand, Quyen Le Nguyen, Sandra Nolte, Felix A Ogbo, Kelechi E Oladimeji, Eyal Oren, Mahesh Pa, Eun-Kee Park, David M Pereira, Dietrich Plass, Mostafa Qorbani, Amir Radfar, Anwar Rafay, Mahfuzar Rahman, Saleem M Rana, Kjetil Søreide, Maheswar Satpathy, Monika Sawhney, Sadaf G Sepanlou, Masood Ali Shaikh, Jun She, Ivy Shiue, Hirbo Roba Shore, Mark G Shrime, Samuel So, Samir Soneji, Vasiliki Stathopoulou, Konstantinos Stroumpoulis, Muawiyyah Babale Sufiyan, Bryan L Sykes, Rafael Tabarés-Seisdedos, Fentaw Tadese, Bemnet Amare Tedla, Gizachew Assefa Tessema, J S Thakur, Bach Xuan Tran, Kingsley Nnanna Ukwaja, Benjamin S Chudi Uzochukwu, Vasiliy Victorovich Vlassov, Elisabete Weiderpass, Mamo Wubshet Terefe, Henock Gebremedhin Yebyo, Hassen Hamid Yimam, Naohiro Yonemoto, Mustafa Z Younis, Chuanhua Yu, Zoubida Zaidi, Maysaa El Sayed Zaki, Zerihun Menlkalew Zenebe, Christopher J L Murray, Mohsen Naghavi
Importance: Cancer is the second leading cause of death worldwide. Current estimates on the burden of cancer are needed for cancer control planning. Objective: To estimate mortality, incidence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) for 32 cancers in 195 countries and territories from 1990 to 2015. Evidence Review: Cancer mortality was estimated using vital registration system data, cancer registry incidence data (transformed to mortality estimates using separately estimated mortality to incidence [MI] ratios), and verbal autopsy data...
December 3, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27887709/impact-of-tamoxifen-therapy-on-fertility-in-breast-cancer-survivors
#9
Lisa M Shandley, Jessica B Spencer, Amy Fothergill, Ann C Mertens, Amita Manatunga, Elisavet Paplomata, Penelope P Howards
OBJECTIVE: To determine whether tamoxifen use is associated with decreased ovarian reserve and decreased likelihood of having a child after a breast cancer diagnosis, using data from the Furthering Understanding of Cancer, Health, and Survivorship in Adult (FUCHSIA) Women Study. DESIGN: Population-based cohort study. SETTING: Not applicable. PATIENT(S): Three hundred ninety-seven female breast cancer survivors aged 22-45 years whose cancer was diagnosed between ages 20 and 35 years and who were at least 2 years after diagnosis; 108 survivors also participated in a clinic visit...
January 2017: Fertility and Sterility
https://www.readbyqxmd.com/read/27848252/feasibility-and-effects-of-a-decision-aid-about-fertility-preservation
#10
Mirjam M Garvelink, Moniek M Ter Kuile, Leoni A Louwé, Carina G J M Hilders, Anne M Stiggelbout
This paper reports on the feasibility and preliminary effects of a decision aid (DA) about female fertility preservation (FP). We conducted a pilot multicentre randomized controlled trial of women with breast cancer aged 18-40 who were randomized to brochures or the DA. Over 18 months, 62 women were eligible, of which 42 were invited by their healthcare provider (74%) to participate in the study. A total of 36 women signed up for participation and 26 (72%) were randomized to brochures (n = 13) or the DA (n = 13)...
November 16, 2016: Human Fertility: Journal of the British Fertility Society
https://www.readbyqxmd.com/read/27845854/on-site-fertility-preservation-services-for-adolescents-and-young-adults-in-a-comprehensive-cancer-center
#11
Mary Peavey, Sara Arian, William Gibbons, Karen Lu, David Gershenson, Terri Woodard
PURPOSE: Adolescents and young adults (AYAs) receiving cancer treatments that may impair fertility should receive counseling about risk of infertility and options for fertility preservation (FP) before treatment and/or during survivorship. Our objective was to define the AYA patient population referred to an on-site fertility consultation service within a comprehensive cancer center and determine factors associated with patients proceeding with FP treatment. METHODS: We conducted a retrospective chart review of AYA women who completed a consultation at the MD Anderson Fertility Preservation and Family Building Service during the first year of service...
November 15, 2016: Journal of Adolescent and Young Adult Oncology
https://www.readbyqxmd.com/read/27836531/childhood-sexual-abuse-and-early-timing-of-puberty
#12
Jennie G Noll, Penelope K Trickett, Jeffrey D Long, Sonya Negriff, Elizabeth J Susman, Idan Shalev, Jacinda C Li, Frank W Putnam
PURPOSE: The purpose was to examine whether the timing of puberty, indexed by breast development and pubic hair development, was earlier for sexually abused females compared with a matched comparison group of nonabused females, controlling for key alternative confounds. METHODS: A cohort of sexually abused females and matched comparisons was followed longitudinally at mean ages 11 through 20 years. Sexually abused participants (N = 84) were referred by protective services...
January 2017: Journal of Adolescent Health: Official Publication of the Society for Adolescent Medicine
https://www.readbyqxmd.com/read/27801578/does-proton-conduction-in-the-voltage-gated-h-channel-hhv1-involve-grotthuss-like-hopping-via-acidic-residues
#13
Siri Camee van Keulen, Eleonora Gianti, Vincenzo Carnevale, Michael L Klein, Ursula Rothlisberger, Lucie Delemotte
Hv1 are ubiquitous highly selective voltage-gated proton channels involved in male fertility, immunology and the invasiveness of certain forms of breast cancer. The mechanism of proton extrusion in Hv1 is not yet understood while it constitutes the first step towards the design of high-affinity drugs aimed at this important pharmacological target. In this contribution, we explore the details of the mechanism via an integrative approach, using classical and QM/MM molecular dynamics simulations of a monomeric hHv1 model...
November 1, 2016: Journal of Physical Chemistry. B
https://www.readbyqxmd.com/read/27761367/the-role-of-micrornas-in-bone-metastasis
#14
Eugenio Zoni, Gabri van der Pluijm
The skeleton represents a common site of metastases for osteotropic cancers such as prostate and breast tumors and novel therapeutic targets and new markers for the monitoring of bone lesions are urgently needed. The formation of bone metastases is a complex process that starts at the level of the confined tumor and that is characterized by a dynamic crosstalk between the primary cancer and the future metastatic site, the bone. Factors released by the primary tumor contribute to prepare a fertile "soil", where a "pre-metastatic niche" is established prior to future colonization by cancer cells...
September 2016: Journal of Bone Oncology
https://www.readbyqxmd.com/read/27738376/paroxetine-the-antidepressant-from-hell-probably-not-but-caution-required
#15
REVIEW
Robert M Nevels, Samuel T Gontkovsky, Bryman E Williams
Paroxetine, also known by the trade names Aropax, Paxil, Pexeva, Seroxat, Sereupin and Brisdelle, was first marketed in the U.S. in 1992. Effective for major depression and various anxiety disorders, it quickly gained a sizable share of the antidepressant prescription market. By the late 1990s, paroxetine frequently was being associated with serious drug interactions and medication side effects. Most significantly, in a major Canadian epidemiological study examining the relationship between antidepressants and diseases, paroxetine was associated with a 620 percent increase in the rate of breast cancer in women who had taken it over a four-year period...
March 1, 2016: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/27733017/short-term-and-long-term-effects-of-tibolone-in-postmenopausal-women
#16
REVIEW
Giulio Formoso, Enrica Perrone, Susanna Maltoni, Sara Balduzzi, Jack Wilkinson, Vittorio Basevi, Anna Maria Marata, Nicola Magrini, Roberto D'Amico, Chiara Bassi, Emilio Maestri
BACKGROUND: Tibolone is a synthetic steroid used for the treatment of menopausal symptoms, on the basis of short-term data suggesting its efficacy. We considered the balance between the benefits and risks of tibolone. OBJECTIVES: To evaluate the effectiveness and safety of tibolone for treatment of postmenopausal and perimenopausal women. SEARCH METHODS: In October 2015, we searched the Gynaecology and Fertility Group (CGF) Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase and PsycINFO (from inception), the Cumulative Index to Nursing and Allied Health Literature (CINAHL) and clinicaltrials...
October 12, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27723074/breast-cancer-in-young-women
#17
Barbara Radecka, Maria Litwiniuk
Breast cancer (BC) in young women is rare, affecting only 4-6% of women under the age of 40. Regardless, BC remains the most common malignancy among younger patients. Recently, a significant increase in BC rates has been observed among pre-menopausal subjects. Breast cancer in young women requires special attention due to its specific morphologic and prognostic characteristics and unique aspects, including fertility preservation and psychosocial issues (e.g. its impact on family life and career). Young women are more likely to have tumors with higher incidence of negative clinicopathologic features (higher histological grade, more lymph node positivity, lower estrogen receptor (ER) positivity, higher rates of Her2/neu overexpression)...
2016: Ginekologia Polska
https://www.readbyqxmd.com/read/27664208/factors-associated-with-ovarian-function-recovery-after-chemotherapy-for-breast-cancer-a-systematic-review-and-meta-analysis
#18
Cristina Silva, Olga Caramelo, Teresa Almeida-Santos, Ana Cristina Ribeiro Rama
STUDY QUESTION: Which factors related to patient, treatment or disease are associated with ovarian function recovery after chemotherapy in premenopausal women with breast cancer? SUMMARY ANSWER: Younger age and GnRH agonist (GnRHa) administration during chemotherapy were significantly associated with menses recovery, but this recovery was less likely in patients exposed to taxanes. WHAT IS ALREADY KNOWN: To date, published meta-analyses have only assessed GnRHa administration as a possible factor for ovarian function recovery, and their results were conflicting...
December 2016: Human Reproduction
https://www.readbyqxmd.com/read/27660470/incidence-and-mortality-rates-in-breast-corpus-uteri-and-ovarian-cancers-in-poland-1980-2013-an-analysis-of-population-based-data-in-relation-to-socioeconomic-changes
#19
Tomasz Banas, Grzegorz Juszczyk, Kazimierz Pitynski, Dorota Nieweglowska, Artur Ludwin, Aleksandra Czerw
OBJECTIVES: This study aimed to analyze incidence and mortality trends in breast cancer (BC), corpus uteri cancer (CUC), and ovarian cancer (OC) in Poland in the context of sociodemographic changes. MATERIALS AND METHODS: Incidence and mortality data (1980-2013) were retrieved from the Polish National Cancer Registry, while socioeconomic data (1960-2013) were obtained from the World Bank. Age-standardized incidence and mortality rates were calculated by direct standardization, and join-point regression was performed to describe trends using the average annual percentage change (AAPC)...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27648726/the-psychosocial-experiences-of-women-with-breast-cancer-across-the-lifespan-a-systematic-review
#20
Heather J Campbell-Enns, Roberta L Woodgate
OBJECTIVE: To summarize the psychosocial experience of women with breast cancer from a lifespan perspective by examining the findings of qualitative studies. METHODS: A meta-aggregate review of 24 qualitative studies was undertaken. To be included, studies must include women with a breast cancer diagnosis and focus on younger or older women (as defined by the study), or compare a psychosocial issue across the lifespan. Eight databases were searched systematically...
September 20, 2016: Psycho-oncology
keyword
keyword
84273
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"